|
|
|
Insider
Information: |
Bvf Inc/il |
Relationship: |
Indirect Beneficial Ow... |
City: |
|
State: |
|
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
12 |
|
Direct
Shares |
49,829,941 |
|
Indirect Shares
|
136,880,248 |
|
|
Direct
Value |
$2,331,544,760 |
|
|
Indirect Value
|
$6,986,791,955 |
|
|
Total
Shares |
186,710,189 |
|
|
Total
Value |
$9,318,336,715 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
19
|
2
|
Stock
price went up :
|
18
|
0
|
Stock
price went down : |
1
|
2
|
|
|
|
Gain/Loss Ratio : |
18.0
|
-2.0
|
Percentage
Gain/Loss : |
64.8%
|
-200.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Neurocrine Biosciences Inc |
NBIX |
10% Owner |
2010-04-12 |
5,041,447 |
2010-04-12 |
15,124,341 |
Premium* |
|
NPS Pharmaceuticals Inc |
NPSP |
Indirect Beneficial Ow... |
2008-03-11 |
0 |
2008-09-22 |
4,383,115 |
Premium* |
|
Astex Pharmaceuticals Inc |
ASTX |
Indirect Beneficial Ow... |
2008-05-01 |
0 |
2008-05-09 |
5,753,399 |
Premium* |
|
Neurobiological Technologies Inc |
NTII |
10% Owner |
2009-10-21 |
331,998 |
2009-10-21 |
995,994 |
Premium* |
|
Epirus Biopharmaceuticals Inc |
EPRS |
10% Owner |
2009-12-22 |
6,830,972 |
2009-12-22 |
20,492,916 |
Premium* |
|
Capstone Therapeutics Corp |
CAPS |
Indirect Beneficial Ow... |
2008-10-10 |
0 |
2008-10-14 |
5,136,888 |
Premium* |
|
Adolor Corp |
ADLR |
Indirect Beneficial Ow... |
2008-10-10 |
4,428,032 |
2008-10-31 |
6,214,551 |
Premium* |
|
Dynavax Technologies Corp |
DVAX |
10% Owner |
2009-09-10 |
4,278,851 |
2009-09-10 |
12,836,553 |
Premium* |
|
Ligand Pharmaceuticals Inc |
LGND |
Indirect Beneficial Ow... |
2009-07-01 |
15,169,950 |
2009-07-01 |
45,509,850 |
Premium* |
|
Curis Inc |
CRIS |
Indirect Beneficial Ow... |
2009-02-03 |
8,921,716 |
2009-04-27 |
5,951,716 |
Premium* |
|
Repligen Corp |
RGEN |
Indirect Beneficial Ow... |
2009-07-07 |
2,765,050 |
2009-07-07 |
8,295,150 |
Premium* |
|
Gyre Therapeutics |
GYRE |
Indirect Beneficial Ow... |
2009-10-16 |
2,061,925 |
2009-10-16 |
6,185,775 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
195 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 2 of 8
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
ARNA |
Arena Pharmaceuticals Inc |
Indirect Beneficial Owner |
|
2004-06-28 |
4 |
S |
$5.30 |
$287,010 |
I/I |
(54,000) |
1,476,351 |
|
- |
|
ARNA |
Arena Pharmaceuticals Inc |
Indirect Beneficial Owner |
|
2004-06-29 |
4 |
S |
$5.31 |
$376,797 |
I/I |
(71,000) |
1,441,351 |
|
- |
|
ARNA |
Arena Pharmaceuticals Inc |
Indirect Beneficial Owner |
|
2004-07-01 |
4 |
S |
$5.42 |
$514,900 |
I/I |
(95,000) |
1,395,351 |
|
- |
|
ARNA |
Arena Pharmaceuticals Inc |
Indirect Beneficial Owner |
|
2004-07-07 |
4 |
S |
$5.10 |
$3,885,176 |
I/I |
(761,288) |
1,026,851 |
|
- |
|
ARNA |
Arena Pharmaceuticals Inc |
Indirect Beneficial Owner |
|
2004-07-08 |
4 |
S |
$5.00 |
$334,000 |
I/I |
(66,800) |
994,851 |
|
- |
|
ARQL |
Arqule Inc |
Indirect Beneficial Owner |
|
2003-07-17 |
4 |
B |
$3.90 |
$2,340 |
I/I |
600 |
2,424,023 |
1.42 |
- |
|
ARQL |
Arqule Inc |
Indirect Beneficial Owner |
|
2008-01-09 |
4 |
B |
$4.29 |
$525,966 |
I/I |
122,700 |
5,606,550 |
1.5 |
- |
|
ARQL |
Arqule Inc |
Indirect Beneficial Owner |
|
2008-01-10 |
4 |
B |
$4.26 |
$1,415,268 |
I/I |
324,227 |
5,930,777 |
1.5 |
- |
|
ARQL |
Arqule Inc |
Indirect Beneficial Owner |
|
2008-01-14 |
4 |
B |
$4.50 |
$111,600 |
I/I |
24,800 |
5,955,577 |
1.5 |
- |
|
ARQL |
Arqule Inc |
Indirect Beneficial Owner |
|
2008-01-15 |
4 |
B |
$4.65 |
$498,655 |
I/I |
107,300 |
6,062,877 |
1.5 |
- |
|
ARQL |
Arqule Inc |
Indirect Beneficial Owner |
|
2008-01-23 |
4 |
B |
$4.47 |
$690,969 |
I/I |
154,600 |
6,217,477 |
1.5 |
- |
|
ARQL |
Arqule Inc |
Indirect Beneficial Owner |
|
2008-01-31 |
4 |
B |
$4.71 |
$2,404,548 |
I/I |
510,000 |
6,727,477 |
1.5 |
- |
|
ARQL |
Arqule Inc |
Indirect Beneficial Owner |
|
2008-02-01 |
4 |
B |
$5.00 |
$825,528 |
I/I |
165,000 |
6,892,477 |
1.5 |
- |
|
ARQL |
Arqule Inc |
Indirect Beneficial Owner |
|
2008-02-04 |
4 |
B |
$5.08 |
$1,068,085 |
I/I |
210,100 |
7,102,577 |
1.5 |
- |
|
ARQL |
Arqule Inc |
Indirect Beneficial Owner |
|
2008-02-07 |
4 |
B |
$4.90 |
$1,803,970 |
I/I |
368,300 |
7,470,877 |
1.5 |
- |
|
ARQL |
Arqule Inc |
Indirect Beneficial Owner |
|
2008-02-08 |
4 |
B |
$4.98 |
$1,289,406 |
I/I |
259,000 |
7,729,877 |
1.5 |
- |
|
ARQL |
Arqule Inc |
Indirect Beneficial Owner |
|
2008-02-11 |
4 |
B |
$4.96 |
$414,851 |
I/I |
83,700 |
7,813,577 |
1.5 |
- |
|
ARQL |
Arqule Inc |
Indirect Beneficial Owner |
|
2008-02-15 |
4 |
B |
$5.08 |
$252,072 |
I/I |
49,600 |
7,863,177 |
1.5 |
- |
|
ARQL |
Arqule Inc |
Indirect Beneficial Owner |
|
2008-02-19 |
4 |
B |
$5.10 |
$164,707 |
I/I |
32,300 |
7,895,477 |
1.5 |
- |
|
ARQL |
Arqule Inc |
Indirect Beneficial Owner |
|
2008-02-20 |
4 |
B |
$5.05 |
$141,905 |
I/I |
28,100 |
7,923,577 |
1.5 |
- |
|
ARQL |
Arqule Inc |
Indirect Beneficial Owner |
|
2008-02-21 |
4 |
B |
$4.95 |
$920,905 |
I/I |
186,000 |
8,109,577 |
1.5 |
- |
|
ARQL |
Arqule Inc |
Indirect Beneficial Owner |
|
2008-02-22 |
4 |
B |
$4.75 |
$38,950 |
I/I |
8,200 |
8,117,777 |
1.5 |
- |
|
ARQL |
Arqule Inc |
Indirect Beneficial Owner |
|
2008-03-10 |
4 |
B |
$3.90 |
$5,316,804 |
I/I |
1,363,283 |
9,481,060 |
1.5 |
- |
|
ARQL |
Arqule Inc |
Indirect Beneficial Owner |
|
2008-11-10 |
4 |
B |
$2.35 |
$3,145,475 |
I/I |
1,338,500 |
10,819,560 |
1.5 |
- |
|
ARQL |
Arqule Inc |
Indirect Beneficial Owner |
|
2008-11-11 |
4 |
B |
$2.25 |
$927,450 |
I/I |
412,200 |
11,231,760 |
1.5 |
- |
|
195 Records found
|
|
Page 2 of 8 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|